RECOMBINANT HUMANIZED ANTI-HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY

Abstract: The present invention provides human monoclonal antibodies, derived from the murine mAb NM-01 (PCT/US92/07111), which are specifically reactive with HIV gp120 and have the capacity to neutralise the infection of H9 cells in culture by live HIV-1 strains MN and IIIB as shown by reverse transcriptase, p24 and syncytium formation assays. These antibodies were shown to be as or more effective than the parent murine antibody by the aforementioned criteria.

Description: RECOMBINANT HUMANIZED ANTI-HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY Field of the Invention The present invention is related to the field of molecular biology in general, and the field of humanized antibodies in particular. Background This application is related to International Patent Application No. PCT/US92/07111, filed on August 24, 1992, which describes materials and methods useful in the prevention and treatment of Human Immunodeficiency Virus (HIV-1) infection and, specifically, monoclonal antibodies useful in passive immunisation of HIV-1 susceptible or infected animals, especially humans. This application gives a background to HIV-1 infection and its prophylactic or therapeutic treatment by passive immunisation, the main points of which are reiterated here. The infective process of HIV-1 in vivo has been reviewed by McCune Cell, 6 pp. 351-363 (1991). HIV-1 infects cell lineages which express the CD4 receptor. Most of these cells are quiescent only dividing in response to specific signals, and so HIV-1 infection results in CD 4 " cells to replicate whereupon viral particles are produced, spreading the infection. Since it is inadvisable to stimulate the immune response of ar HIV-1 infected animal, it may be that the best way to prevent or treat HIV-1 infection is by υassive immunisation. This involves the administration of anti- HIV-1 antibody to the patient, and presumably, it would be desirable for this antibody agent to be non- immunogenic. There is a precedence for such treatment. Human patients suffering advanced acquired immunodeficiency syndrome (AIDS) , the syndrome of progressive immune system deterioration associated with SUBSTITUTE SHEET HIV-1 infection, were given plasma containing antibodies against HIV-1 and showed a temporary reduction in various disease parameters (Jackson et al., Lancet, 2_, pp. 647- 652, 1988). Also the administration of HIV-1 specific antibody to a chimpanzee, prior to exposure to HIV-1, resulted in the animal remaining free of signals of viral infections (Emini et al., Nature, 355, pp. 728-730, 1992) . The HIV-1 major external envelope glycoprotein, gpl20, binds to cellular CD4 receptor and facilitates the internalisation of the virus. Several epitopes of gpl20 have been associated with the development of neutralising antibodies with the so-called "principle neutralising determinant" being localised to the "V3 loop" of gpl20, as referenced in the previous Application (PCT/US92/07111) . The V3 loop consists of a hypervariable domain which is established by disulphie bonding between cystein residues flanking the domain. The PCT Published Patent Application No. PCT/US92/0711 cites examples of antibody reactive to V3 loop which are isolate or type specific and also candidates as broadly neutralising antibodies, although none of these were proven to neutralise multiple strains of live HIV-1. The patterns of reactivity shown by these antibodies are likely to be related to the array of primary sequences and conformations of the V3 loop. The aforementioned Application also highlights potential inadequacies of such antibodies: CD4 may not be the only cellular receptor responsible for viral infectivity (Cheng-Mayer et al., Proc. Natl. Acad. Sci. USA, 84, pp. 3526-3530, 1987) and antibody/HIV-1 complexes may enhance virus replication by, for example, promoting the infection of monocytes via receptor-medicated endocytosis (Takeda et al., Science, 242, pp. 580-583, 1988). Previous work had shown that certain animal virus are . inactivated by complement, particularly Clq, through an SUBSTITUTE SHEET antibody-independent mechanism (see, for example Weiss, in Molecular Biology of Tumour Viruses, RNA Tumour Viruses, Weiss et al., Eds., Cold Spring harbour Laboratory, New York , pp. 1219-1220, 1982). While Banapour et al., Virology, 252. pp. 268 271 (1986) describe unheated serum preparation as having no effect on the density of HIV-1 or its ability to infect peripheral blood mononuclear cells, Spear et al., J. Virol. , 64., pp. 5869-5873 (1990) report that HIV-1 treated with a combination of complement and pooled sera from HIV-1 sero-positive patients exhibits reduced infectivity. Thus the background to the previous invention (PCT/US92/07111) was the identification of a need for new monoclonal antibody substances which are specifically immunoreactive with HIV-1 and which, preferably, would neutralise multiple HIV-strains. As candidates for use in passive immunisation of infected non-infected patients, these agents would ideally be able to medicate complement-dependent virolysis of HIV-1 particles and antibody-dependant cytolysis of HIV-1 infected cells. The aforementioned invention (PCT/US92/07111) provides monoclonal antibodies reactive to the portion of HIV-1 gpl20, or the precursor of gpl60, comprising the amino acid sequence GPGR, characterised by their capacity to neutralise the infection of H9 cells in culture by live HIV-1 strains MN and III S and to mediate complement- dependent virolysis of HIV-1 particles and or antibody- dependent cellular cytoxicity of HIV-1 infected cells. It was suggested that the monoclonal antibodies of the invention would be suitable for use in anti-HIV-1 treatment of animals, especially humans, susceptible to or infected with HIV-1. Within the contemplation of the invention was the similar use of chimaeric antibodies, humanised antibodies, antibody fragment or bispecific antibodies, which could be made as derivatives of the SUBSTITUTE SHEET antibodies of the invention, and the use of products of the invention in combination with other immunological and/or therapeutic agents. The invention describes generation of monoclonal antibodies by immunization of a suitable host with live hIV-1, thus presenting gpl20 in its native conformation. It is illustrated by the murine monoclonal antibody, NM- 01, produced by the hybridoma cell line HB 10726. The efficacy of NM-01 in .in vitro assay, the mapping of the epitope of NM-01 to the sequence GPGR of the gpl20 V3 loop and the determination the NM-01 heavy and light chain variable region sequences are described. It might be expected that a human antibody would be more suitable than a xenogeneic antibody in prophylactic and therapeutic treatment of HIV-1 infection in humans. This is because the human antibody would be less immunogenic than, for example, a murine counterpart (Bruggermann et al., J Exp Med, 170, pp. 2153-2157, 1989) and may, depending on the isotype involved, be more efficient at triggering complement-dependent virolysis and antibody-dependent cellular cytoxicity of HIV-1 infected cells (discussed by Winter and Milstein Nature, 349, 293-299, 1991) . To secure the advantages of a human antibody, whilst making use of the antigen-binding properties of an antibody raised in a different species, workers have used the technique of humanisation to transfer the antigen- binding loops to a human template (for example Riechmann et al., Nature, 332, pp. 323-327, 1988; Tempest et al., Bio/Technology, 9., pp. 266-271, 1991) . These loops, known as complementarity determining regions (CDRs) are mounted on a scaffold - the frameworks regions - which together make up the so-called variable domains, situated at the N-terminal ends of each antibody chain. Each binding site is formed, in the most part, from three heavy chain and three light chain CDRs, although SUBSTITUTE SHEET framework residues can interact with antigen, either directly or indirectly, by altering the CDR conformation. Genes encoding these recombinant antibodies are expressed in, for example, mammalian cells, and their constant region components can be tailored to suit the application. Brief Summary The present invention provides human monoclonal antibodies, derived from the murine mAb NM-01 (PCT/US92/07111) , which are specifically reactive with HIV gpl20 and have the capacity to neutralise the infection of H9 cells in culture by live HIV-1 strains MN and III B as shown by reverse transcriptase, p24 and syncytium formation assays. These antibodies were shown to be as or more effective than the parent murine antibody by the aforementioned criteria. The monoclonal antibodies according to this invention are especially suitable for use in anti-HIV-1 treatment of humans as they are likely to be less immunogenic than xenogenic antibodies and more effective in complement- dependent virolysis of HIV-1 particles and/or antibody- dependant cellular cytoxicity of HIV-1 infected cells. As set forth in the following detailed description, monoclonal antibodies of the present invention were created as human igGl/K antibodies by humanisation of the murine mAb NM-01. The aspects and advantages of the present invention will be apparent upon consideration of the illustrative examples and descriptions of practice of the present invention in the following detailed description thereof, reference being made to the drawings wherein: Figure 1 contains the nucleotide sequence of the murine NM-01 heavy chain variable region (VH) cDNA (SEQ ID No. 8) and the translation product (SEQ ID No. 9) . The CDRs are boxed. SUBSTITUTE SHEET Figure 2 shows the nucleotide (SEQ ID No. 10) and amino acid (SEQ ID No. 11) sequences of the murine kappa chain variable region (VK cDNA) . The CDRs boxed. Figure 3 is a graph showing the ability of various recombinant NM-01 antibodies to bind to recombinant gpl20 as judged by ELISA. Figure 4 shows two comparisons of amino acid sequences. In figure 4a, the murine NM-01 VH (MuVH) is aligned with its humanised counterpart (HuVH, SEQ ID No. 13) . The CDRs are boxed. The indicated framework residues are the murine residues which were incorporated into the humanised chain as discussed in Example 3. In figure 4b, the murine NM-01 VK is compared to the humanised NM-01 VK (HuVK, SEQ ID No. 14) . The CDRs are boxed. F71 of the MuVK, which was included in the HuVKF chain, is indicated. Figure 5, is a pair of graphs showing the binding of NM-01 antibodies to a lysate of MN virus (a) or mutant MN virus (b) in an ELISA. Figure 6 is a graph depicting the results of an ELISA in which the listed antibodies were tested for their ability to bind to a loop peptide, representing residues 312-326 of HIV-l MN gpl20. Figure 7 shows the ability of various NM-01 antibodies to block the binding of labelled murine NM-01 antibody to recombinant gpl20. Figures 8-11 demonstrate the neutralising activity of various NM-01 antibodies against MN and III 3 strains of HIV-1 as determined by reverse transcriptase and p24 assays. Figure 12 shows the ability of the listed antibodies to inhibit syncytium formation of the MN strain of HIV-1. Examples The following examples illustrate the practice of the invention in the generation of a humanised monoclonal SUBSTIT antibody reactive with HIV-1 gpl20. The eaxmples are given for the purpose of illustrating the claimed invnetion and should not be construed as a limitation of the claimed invention. More particularly, Example 1 describes the determination of the amino acid sequences of the variable regions of the parent NM-01 murine antibody. Examples 2 and 3 are directed to the generation of chimaeric and humanised NM-01 antibodies and Example 5 describes the assessment of the biological activity of this humanised antibody. Example 1 Isolation of the DNA sequences encoding murine NM-01 variable regions. The variable region sequences were disclosed in Application PCT/US92/07111 and were confirmed by independent isolation as described here. The sequences were determined from heavy and light chain cDNAs which were synthesised from cytoplasmic RNA, essentially as described by Tempest et al., loc cit. 1. RNA isolation Approximately 200μg cytoplasmic RNA was isolate from 10' NM-01-producing hybridoma cells by the method of Favalora et a. Meth Enzvmol, 65, pp. 718-749 (1980) . Supernatant obtained from the culture of these cells was assayed for the presence of antibody by solid-phase ELISA using an Inno-Lia mouse monoclonal antibody isotyping kit (Innogenetics, Antwerp, Belgium) . The antibody was confirmed to be IgG 2fc /K by this method. 2. cDNA synthesis Reverse transcription of NM-01 RNA was initiated from primers based on the 5 1 end of either the murine IgG 2 ./IgG 2 (CG2FOR, SEQ ID No. 1) or the murine Kappa SUBSTITUTE SHEET (CK2FOR, SEQ ID No. 2) constant region genes. The reactions consisted of 5μg RNA, 5μg CG2F0R or CK2F0R, 250μg each dATP, dCTP, dGTP and dTTP, 50mM Tris-Hcl pH 8.3, 75mM Kcl, lOmM DTT, 3mM MgCl 2 , 30 units RNase inhibitor (Pharmacia Milton Keynes, United Kingdom) in 50μg total volume. Samples were heated at 70°C for 10 min and then cooled to 37°C over 30 min. 100 units M-MLV reverse transcriptase (Life Technologies, Paisley, United Kingdom) was added and the reaction allowed to proceed at 37°C for 1 hour. 3. Amplification of VH and VK cDNA The murine variable region cDNAs were amplified by the PCR (Saiki et al. Science, 239, 498-491, 1988) using variable region primers, including those described by Orlandi et al., Proc. Natl. Acad Sci USA, 86, pp. 3833- 3837 (1989), and signal sequence primers, derived from those of Jones and Bendig, Bio/Technology, 9_, 88-89 (1991) , as well as the constant region primers which were involved in the first strand cDNA synthesis. Several primers gave successful amplification. These additional primers were based conserved regions at the 5' end of either murine VH (VHIBACK, SEQ ID No. 3) or murine VK (VK1BACK, SEQ ID No. 4) genes or the 3' end of murine VH genes (VH1FOR, SEQ ID No. 5) . Other primers were designed from signal sequence genes of murine heavy SH3BACK, SEQ ID No. 6) or Kappa (SK5BACK, SEQ ID No. 7) chains. For PCR amplification of the VH, the reactions contained 5μg RNA/cDNA hybrid, 0.5μM CG2FCR and 0.5μ VHIBACK or SH3BACK. For the VK, 5μl RNA/cDNA hybrid was amplified with 0.5μM each CK2FOR and VK1BACK or SK5BACK. In addition each reaction contained 250μM each dATP, dCTP, dGTP and dTTP, lOmM Tris-Hcl pH 8.3, 50mM KC1, 1.5mM MgCl 2 , 0.01% (w/v) Tween 20, 0.01% (v/v) NP-40 and -3 units AmpliTaq (Perkin Elmer Cetus, Beaconsfield, UK). SUBSTITUTE SHEET Amplification was over 25 cycles of 94°C, 30s; 50 or 55°C, 30s; 72°C, 45s plus 72°C 5 min to end. To increase specificity, the product of the VH reaction with CG2F0R and SH3BACK was further using VH1FOR and SH3BACK. The VH product sizes were approximately 400 bp (CG2FOR, VHIBACK) and 440 bp (VH1F0R, SH3BACK) as visualized by agarose gel electrophoresis. The VK products were of about 37 bp (CK2FOR, VK1BACK and 440 bp CK2FOR, SK5BACK) . These DNAs were purified by electrophoresis on low melting point agarose and Elutip-d column chromatography (Schleider and Schuell, Dassel, Germany) . 4. Cloning and Sequencing VH cDNA General cloning methodology is described in Maniatis et al. Molecular cloning, a laboratory manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 1982) . Enzymes were obtained from Life Technologies (Paisley, United Kingdom) . The CG2F0R, VHIBACK product was cloned into M13 mpl8 and M13mpl9 (Pharmacia, Milton Keynes, United Kingdom) using the Hindlll and PstI restriction sites incorporated into the PCR primers. Clones were sequenced by the dideoxy method (Sanger et al., Proc. Natl. Acad. Sci. USA, 74 pp. 5463-5467, 1977) using T7 DNA polymerase (Pharmacia, Milton Keynes, United Kingdom) . The majority of clones, of which seven were sequenced for the entire insert, contained an identical complete VH gene by comparison with know sequences and represent both fragment orientations. One clone contained a PCR-induced transition mutation. The only other sequence obtained was unidentified but was not VH-like. As the sequence at the N-terminus of the VH was dictated by the. VHIBACK primer, product of the VH1FOR and SH3BACK reaction was cloned to identify the genuine residues. The product was cloned using Sail restriction, site of SH3BACK and the BamHI site which is internal to SUBSTITUTE the VH fragment. The 5 1 VH sequence was obtained from two clones. The complete VH nucleotide sequence and the amino acid sequence derived by translation are shown in figure 1 (SEQ ID Nos. 8 and 9) . The extent of the CDRs indicate were determined as defined by Kabat et al., Sequences of proteins of Immunological Interest (5th edition), U.S. Department of Health and Human Services (1991) . These differ from those shown in Application PCT/US92/07111. 5. Cloning and sequencing VK cDNA The primers used in the amplification of VK cDNA also contain restriction sites such that the CK2FOR, VHIBACK product was cloned as Hindlll - PvuII fragments and the CK2FOR, SK5BACK product as Hindlll - Sail fragments into M13mpl8 and M13mpl9. The majority (26/31) of clones sequenced contained the same VK insert, identified by homology with known VK sequences. This was obtained from both PCR products in both orientations. The sequence of 21 clones was read for at least 200 nucleotides and, in the case of 14 clones, for the entire VK. There were four PCR-induced point mutations. Of the other clones obtained most had unidentified inserts but one contained a VK-like sequence which would be non-productive due to the lack of the conserved cysteine residue at Kabat position 23 and a frameshift within the DNA encoding CDR3. The sequence has been obtained from RNA of other hybridoma cells and is believed to originate from the fusion partner (unpublished data) . The NM-01 VK nucleotide sequence, including the genuine 5 1 residues as obtained from CK2F0R, SK5BACK product, is shown in figure 2 together with its amino acid translation product (SEQ ID Nos. 10 and 11) . Again the CDrs, by the definition of Kabat et al., loc. cit, differ from those indicated in Application PCT/US92/07111. SUBSTITUTE SH Example 2 Production of chimaeric NM-01 antibody The production of a chimaeric antibody, consisting of murine variable and human constant regions, is not necessary to the humanisation process but can be useful as its ability to bind antigen can suggest that the correct VH and VK have been cloned from the cDNA of the hybridoma and the antibody can be used as a control in assays to assess the efficacy of the humanised antibodies. VH and VK inserts were amplified from M13 clones using the oligonucleotides VH1FOR and VHIBACK or VK1FOR (Orlandi et al., loc. cit.; SEQ ID No. 12) and VK1BAK so that their transfer to chimeric expression vectors could be facilitated by the included restriction sites. The reaction mixtures contained approx. 100 ng M13 cDNA, 0.5uM each primer. 250μM each dATP, dCTP, dGTP and dTTP, 20 mM Tris-HCl pH8.8, lOmM KC1, lOmM (NH 4 ) 2 S0 4 , 2mM MgS0 4 0.1% (v/v) Triton X-100 and 1 unit Vent DNA polymerase (New England Biolabs, Beverly, MA, USA) in 50ul total volumes. The samples were subjected to 10 cycles of 94°C, 30s; 50°C, 30s; 75°C, 1 min. followed by an additional 5 min. at 75°C. The VH product was digested with PstI and BstEII and cloned into M13VHPCR1 (Orlandi et al. , loc. cit.) . The VK product was cloned into the Pvull and Bell sites of M13VKPCR1 (Orlandi et al. , loc. cit. ) . as a Pvull - Bσll fragment. These manipulatios served to place the variable regions behind promoter and signal peptide gene sequences in the correct context for expression but also slightly changed residues at their termini: VH 12 to V; K5 to Q; S108 to T VK V3 to Q; L106 to 1 UBSTI TE HE These expression cassettes were sequenced completely to confirm the absence of spurious mutations and were then excised from M13 RF DNA as Hindlll - BamHI fragments. Partial BamHI digestion was employed so that full length fragments, .not cut at the BamHI sites internal to the VH and VK, could be obtained. The VH fragment was cloned in to a derivative of pSVgpt (Orlandi et al., loc. cit.) which contains a human IgGl constant region gene (Takahashi et al., Cell 29, pp. 671-679, 1982). The VK fragment was cloned into pSVhyg (Orlandi et al., loc. cit.) , already containing the human kappa constant region gene (Hieter et al., Cell, 22 , pp 197-207, 1980). The vectors were contransfected into the rat myeloma YB2/0 (Kilmartin et al., J. Cell Biol, 93, pp. 576-582, 1982 (69), available from the American Type Culture Collection, Rockville, MD, USA) as previously described (Tempest et al., loc cit) . Mycophenolic acid resistant clones screened by ELISA for secretion of human IgG/K antibody. ELISA positive clones were expanded and antibody purified from culture medium by protein A affinity chromatography. The chimaeric antibody, purified from the transfected cells, was tested by ELISA for binding to recombinant gpl20 (American BioTechnologies Inc., Cambridge, MA, USA). gpl20 (2ng/100μl 15mM Na 2 C0 3 , 35mM NaHC0 3 ph 9.6 per well) was incubated overnight at 4°C in I mulon 2 plates (Dynatech) . The plates were washed with phosphate buffered saline (PBS) - 0.05% Tween 20, blocked with 5% normal goat serum (Life Technologies Paisley, United Kingdom) for lh at 37°C and washed again. Antibodies were added at various concentrations in PBS - 0.05% Tween 20 and incubated at 37°C for 1 h. After washing, HRPO- conjugated goat anti-human kappa chain antibodies (Sera- Lab Limited, Crawley Down, Sussex, England; 40ng/100μl PBS - 0.05% Tween 20 per well) were added. After 1 h, the wells were washed and incubated in the presence of o- SUBSTITUTE SHEET phenyldiamine until colour had developed (5-10 min) . Asorbance was read at 492 n . The results (figure 3) showed the chimaeric antibody (termed MuVH/MuVK) to be reactive against recombinant gpl20. Example 3 Generation of humanised NM-01 antibodies Humanised variable domains are created by transferring the antigen-binding loops of the parent antibody to human variable region frameworks. The frameworks used in the case of NM-01 were those of NEWH VH (Saul et al., J. Biol Chem, 253, pp 585-597, 1978) and REI VK (Epp et al., Eur. J. Biochem, 45, pp. 513-524, 1974). For the humanised heavy chain (HuVH, SEQ ID No. 13) , this involved transfer of the CDRs, as defined by Kabat et al., loc cit. , and an additional five residues from the frameworks (figure 4a) . The four residues prior to CDR1 are not hypervariable and therefore not defined as part of the CDR by Kabat et al., loc cit. but they are part of the loop structure which extends from the β-sheet framework of domain and thus affect the loop conformation. (Chothia and Lesk, J Mol. Biol, 196, pp. 901-917, 1987) . Residue 71 (Kabat numbering) packs between the loops of CDRs 1 and 2 and is important in determining the conformation of CDR2 (Tramontano et al., J Mol. Biol, 215, pp. 175-182, 1990). The basic humanised VK (HuVK, SEQ ID No. 14) contained only the CDR sequences of the murine antibody but a second version (HuVKF) additionally included the murine residue, F, at Kabat position 71 (figure 4b) . The side chain of the amino acid at this position affects the conformation of CDR1 (Chothia and Lesk, loc cit) and reversion to the murine residue has positively affected the binding ability of other humanised antibodies (see, SUBSTITUTE SHEET for example, Foote and Winter, J Mol. Biol, 224, pp. 487- 449, 1992). DNA encoding the NM-01 CDRs and the aforementioned framework residues was introduced into the appropriate human variable region genes, as contained in derivatives of M13VHPCRI and M13VKPCR1 (Example 2), by site directed metagenesis. The M13 phage were grown in E. coli.RZ1032 (dut ung) to give single-stranded template DNA containing uracil in place of thymine. 0.5μg DNA was mixed with lpmol of each mutagenic oligonucleotide and an oligonucleotide which anneals to the M13 template downstream of the insert DNA. The oligonucleotides were annealed to the template in 20ul of 50mM Tris-HCl pH7.5, 25mM MgCl 2 , 63mM NaCl by heating to 80°C for 5 min and cooling slowly to room temperature. dATP, dCTP, dGTP and dTTP were added to 250uM final concentration, DTT to 7mM, ATP to ImM with 0.5 units T7 DNA polymerase (United States Biochemical Cleveland, OH, USA) and 0.5 units T4 DNA ligase (Life Technologies, Paisley, UK) in the same buffer. The 30μl reaction was incubated room temperature, lh and the DNA ethanol precipated. In order to nick the parental strand, the DNA was dissolved in 50μl 60mM Tris HC1 pH8.0, ImM EDTA, ImM DTT, 0.1 mg/ml BSA containing 1 unit uracil DNA glycosylase (Boehringer Mannheim, Lewis, Sussex, UK) and incubated 37°C, lh before NaOH was added to 0.2M and incubation continued at room temperature for 5 min. The DNA was ethanol precipated, dissolved in 20μ.-. TE and the insert fragment amplified by PCR. The reaction mixture contained 2μl mutant DNA, 0.5μM each M13 forward and reverse primers, 250μM each of dATP, dCTP, dGTP and dTTP, lOmM Tris Hcl pH8.3., 50m KC1, 1.5mM MgCl 2 , 0.01% Tween-20, 0.01% gelatin, 0.01% NP40 and 2 units Thermalse (IBI, Cambridge, UK) in 50μl. Amplification was achieved with 15 cycles of 94°C, 30s; 50°C, 30s; 72§C, 1 min; ending with 72°C, 5 min. The product DNAs SUBSTITUTE SHEET were cloned into ml3mpl9 as Hindlll-BamHI fragments. Representative clones were sequenced. the Hindlll-BamHI fragments were excised from RF DNA of accurately-mutated clones and transferred to the pSVgpt and pSvhyg expression vectors are described in Example 2. The transfection of YB2/0 and their selection and expression was carried out as Example 2. As well as transfections to give humanised antibodies (HuVH/HuVK and HuVH/HuVKF) , chimaeric and humanised antibody chain expression vectors were co-transfected to give mixed antibodies which would allow the efficacy of the humanised chains to be examined individually. The antibodies were purified by protein A agarose affinity chromatography and tested for binding to recombinant gpl20 as described in Example 2 (figure 3) . The result indicates that the HuVH and MuVH chains are equivalent, as are the HuVK and MuVK chains with the HuVKF chain giving an advantage of 2-4 fold. This suggests that the NM-01 humanised antibodies (HuVH/HuVK and HuVH/HuVKF) bind well to recombinant gpl20. The antibodies were similarly tested for their ability to bind to Triton X-100 lysate of MN virus and of a mutant MN virus (figure 5a and b) . The signal levels for the murine and recombinant antibodies cannot be compared as different reporter antibodies were used but the MuVH/MuVK, HuVH/HuVK and HuVH/HuVKF antibodies are all seen to bind to MN virus but not to a mutant virus to which NM-01 murine mAb will not bind. Example 4 Determination of the NM-01 HuVH/HuVKF epi ope The epitope of the humanised antibody NM-01 HuVH/HuVKF was investigated by peptide binding and competition ELISAs. ELISA aσainst HIV- 1 peptide SUBSTITUTE SHEET Murine NM-01 binds to a loop peptide representing residues 312-326 of HIV-1 M , gpl20 which includes the GPGR motif. The peptide (synthesised by Multiple Peptide Systems, San Diego, CA, USA) and a negative control peptide, representing a different part of the V3 loop, (both 250ng/100μl 0.1 M sodium borate pH8.0 per well) were incubated overnight at 4°C in Immulon 2 plated (Dynatech) . The plates were washed with PBS -0.05% Tween 20 and blocked with PBS-0.1% Tween 20-0.1% BSA for lh at room temperature. The blocking solution was removed, dilutions of NM-01 antibodies added in blocking solution and incubation continued at 37°C for lh. The plates were washed and HRPO-conjugated goat anti-mouse lgG antibodies (Zymed, San Francisco, CA, USA; 60ng/well) or HRPO- conjugated goat anti-mouse lgG antibodies (Sera-Lab Limited, Crawley Down, Susses, UK; 40ng/well) added. The following incubation at room temperature for lh, the plates were washed and incubated in the presence of o-phenyldiamine until colour had developed (about 5 min) . Absorbances were read at 492 nm. The binding of the NM- 01 antibodies to the HIV-l MN gpl20 residue 312-326 peptide is shown in figure 6, no binding was observed when the negative control peptide was used. The NM-01 NuVH/HuVKF antibody is seen bind the peptide with increased efficiency compared to the chimaeric (MuVH/MuVK) antibody. Direct comparison to the murine NM-01 antibody cannot be made as different conjugated antibodies were used. 2. Completion ELISA against recombinant σp!20 Plates were coated with recombinant gpl20 (5ng/well) and blocked as described in Example 2. Dilutions of NM- 01 antibodies or an irrelevant humanised antibody were added in lOOμl/well and the plates incubated at 37°C for . 30 min. Biotinylateed murine NM-01 antibody (500 mg/50μl SUBSTITUTE SHEET PBS, per well) was added and incubation continued for lh. The plates were washed with PBS - 0.05% Tween 20, HRPO- streptavidin (Sera-Lab Limited, Crawley Down, Sussex, UK, 40ng/100μl PBS, per well) added and incubation continued for 30 min. The plates were washed and incubated in the presence of o-phenyldiamine for 5 min. or until colour developed. Absorbances were read at 492 nm. The result is shown in figure 7 where direct comparison of the murine and recombinant NM-01 antibodies is possible. HuVH/HuVK is as efficient as the murine NM-01 in blocking the binding of labelled murine NM-01 antibody. The HuVH/HuVKF is approximately four-fold more active than the murine antibody whereas the chimaeric (MuVH/HuVK) antibody is slightly deficient relative to the murine antibody -- this is presumably due to the alterations made at the variable region terminal during creation of the chimaeric antibody (Example 2) . The irrelevant humanised antibody shows no blocking activity. These two experiments show that the epitope recognised by the humanised NM-01 antibody, HuVH/HuVKF, is largely, if not completely, identical to that of the murine NM-01 antibody. Example 5 Biological activity of NM-01 HuVH/HuVKF The humanised NM-01 antibody, HuVH/HuVKF, was compared with the murine NM-01 for capacity to neutralise infection of H9 cells by live HIV-I strains MN and IIIB as measured by reverse transcriptase and p24 assays. The antibodies were also compared in a cyncytium formation assay utilising live NM virus. 1. Reverse transcriptase and p24 assays Dilutions of the antibodies were incubated with 100 TCID 50 of MN of III B live virus in 96-well plates for 2h at 4°C. H9 cells (2.5 x 10 5 ) were then added to each well SUBSTITUTE SHEET and the plates were incubated for another hour at 37°C. The H9 cell suspension was then diluted in 2ml RPMI 1640/15% FBS and incubated in a 24 well plate at 37°C. Virus production was determined by reverse transcriptase (RT) assay performed on day 7 as described in Poiesz et al., Proc. Natl. Acad. Sci, USA, 77, pp. 7415-7419 (1980) . The presence of p24 antigen in the tissue culture supernatant was quantitated after 6-8 days by the HIV-1 p24 core profile ELISA, using the method described by the manufacturer (Du Pont - New England Nuclear) . Results are shown in figures 8-12. With the MN strain, 50% neutralisation of RT activity was achieved with 1.2μg/ml murine NM-01 or 0.8μg/ml NM-01 HuVH/HuVKF (figure 8). With strain III 3 , the ID 50 was 0.2μg/ml for murine NM-01 and 0.08μg/ml for NM-01 HuVH/HuVKF (figure 9) . By the p24 assay, 50% neutralisation of MN virus required 1.5μg/ml murine NM-01 or 0.3μl/ml NM-01 HuVH/HvVKF (figure 10) and 50% neutralisation of III B virus required 0.15μg/ml murine NM-01 or 0.08μg/ml NM-01 HuVH/HuVKF (figure 11) . These results demonstrate that NM-01 HuVH/HuVKF is more effective in neutralising NM and III B strains of HIV-1 than the parent murine NM-01. Figure 11 also shows the neutralisation activity of other recombinant NM-10 antibodies and an irrelevant humanised antibody (2990.7 HuVH/HuVK) which acts as a negative control. This results supports that of the competition ELISA which suggested the chimaeric antibody (MuVH/MuVK) was deficient relative to the murine NM-01. The HuVH/HuVK antibody is again seen to be less efficient than the HuVH/HuVKF. The result with the mixed antibody MuVH/HuVKF indicates that the humanised kappa chain, rather than heavy chain, is responsible for the superior activity of HuVH/HuVKF compared to the murine antibody. 2. Syncytium formation assay SUBSTITUTE SHEET The binding inhibition assay was a modification of that described previously in Johnson and Walker, Eds., Techniques in HIV-1, Research, Stockton Press, New York, NY, pp. 92-97 (1990). Briefly, H9 cells chronically infected with MN virus were incubated with dilutions of the antibodies for lh at 37°C. Cells from the indicator cell line C8166 were then added (3 x 10 4 cells/well) and the plate incubated for 2-12h at 37°C. Syncytia greater than three lymphocyte cell diameters were counted and compared to that obtained for control infected H9 cells treated in the absence of antibody. The result is shown in figure 12 and demonstrates that an increased level of inhibition is achieved with the NM- 01 HuVH/HuVKF antibody compared with the murine NM-01. The negative control humanised antibody (2990.7) had no detectable effect. Example 6 Formulations The humanized immunoglobulins of the subject invention and pharmaceutical compositions thereof are particularly useful for parenteral administration, e.g., subcutaneously intramuscularly or intravenously. The compositions for parenteral administration will typically comprise a solution of the humanized immunoglobulin dissolved in a physiologically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., water, buffered water, physiological saline, 0.3% glycine, and the like. Solutions for parenteral administration are preferably sterile and generally free of particulate matter. Compositions for parenteral administration may be lyophilized for convenient storage and rehydrated prior to use. These compositions for parenteral administration may be sterilized by conventional sterilization techniques. The compositions may contain SUBSTITUTE SHEE pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of humanized immunoglobulin in these formulations can vary widely, i.e., from less than about 0.5%, but usually at or at least about 1% to as much as 15% or 20% by weight and maybe selected primarily based on fluid volumes, viscosities,etc. , in accordance with the particular mode of administration selected. Biological Deposits Prior to the filing of this application, Applicants have deposited cell lines with the ECACC that produce the following antibodies as described herein: Hu VHS/Hu VKF G4 (accession # 93082018), Hu VH/Hu VKF C4 (accession # 93082019), Hu VHM/Hu Vk G7 (accession # 93082020), Hu VHM/Hu VKF G8 (accession # 93082021) , Hu VHS/Hu VK F6 (accession # 93082023), and Hu VH/ Hu VK F6 (accession # 93082022) . Availability of the deposited strains is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws. Equivalents All publications and patents mentioned in the above specification are herein incorporated by reference. The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of SUBSTITUTE SHEET molecular biology or related fields are intended to be within the scope of the following claims. SUBSTITUTE SHEET 2? Listing of Sequences SEQ ID No 1 : Single-stranded DNA; CG2FOR 5' GGAAGCTTAGACCGATGGGGCTGTTGTTTTG 3' SEQ ID No 2 : Single-stranded DNA; CK2FOR 5' GGAAGCTTGAAGATGGATACAGTTGGTGCAGC 3' SEQ ID No 3 : Single-stranded DNA; VHIBACK 3' AGGTSMARCTGCAGSAGTCWGG 3" SEQ ID No 4 : Single-stranded DNA; VKIBACK 5' GACATTCAGCTGACCCAGTCTCCA 3' SEQ ID No 5 : Single -stranded DNA; VHIFOR 5' TGAGGAGACGGTGACCGTGGTCCCTTGGCCCCAG 3' SEQ ID No 6 : Single-stranded DNA; SH3BACK 5' TTGTCGACATGATGGTGTTAAGTCTTCTGTACCTG 3" SEQ ID No 7 : Single-stranded DNA; SK5BACK 5ΑAGTCGACATGRRTWTASTCACWCACCTSCTRKSGKT 3' SEQ ID No 8 : Double-stranded DNA; Murine NM-01 VH cDNA See figure 1 SEQ ID No 9 : Protein; murine NM -01 VH See figure 1 SEQ ID No 10 : Double stranded DNA; murine NM-01 VK cDNA See figure 2 SEQ ID No 11 : Protein; murine NM-01 VK See figure 2 SEQ ID No 12 : Single-stranded DNA; VK 1FOR 5' GTTAGATCTCCAGCTTGGTCCC 3' SEQ ID No 13 : Protein; humanised NM-01 VH See figure 4a SEQ ID No 14 : Protein; humanised NM-01 VK See figure 4b <H t ! fT- C;

Claims: CLAIMS 1. A cell line selected from the group consisting of Hu VHS/Hu VKF G4, Hu VH/HU VKF C4, Hu VHM/Hu V G7, Hu VHM/Hu VKF G8, Hu VHS/Hu VK F6, and Hu VH/Hu VH F6. 2. An antibody comprising a polypeptide selected from the group consisting of figure 1 that has been humanized, and figure 2 that has been humanized and figures 4a and 4b. 3. An antibody derived from the cell line according to claim 1. 4. An antibody comprising a polypeptide selected from the group consisting of SEQ ID No. 13 and SEQ ID No. 14 and mutiens thereof. 5. A therapeutic composition for the treatment and or prevention of HIV infections, said composition comprising an antibody according to any one of claims 2, 3 or 4 and a pharmaceutical carrier. 6. A cell line according to claim 1, wherein the cell line is a hybridoma. 7. A polynucleotide comprising a variable region of an antibody according to claim 2, 3 or 4. 2_Λ RECOMBINANT HUMAN ANTI-HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY Abstract The present invention provides human monoclonal antibodies, derived from the murine mAb NM-01 (PCT/US92/07111) , which are specifically reactive with HIV gpl20 and have the capacity to neutralise the infection of H9 cells in culture by live HIV-I strains MN and III B as shown by reverse transcriptase, p24 and syncytium formation assays. These antibodies were shown to be as or more effective than the parent murine antibody by the aforementioned criteria.

Inventors: ARMOUR KATHRYN LESLEY, CARR FRANCIS JOSEPH, HARRIS JOSEPH WILLIAM, ARMOUR, KATHRYN, LESLEY, CARR, FRANCIS, JOSEPH, HARRIS, JOSEPH, WILLIAM
Applicants: ARMOUR KATHRYN LESLEY, CARR FRANCIS JOSEPH, HARRIS JOSEPH WILLIAM, SCOTGEN LTD, ARMOUR, KATHRYN, LESLEY, CARR, FRANCIS, JOSEPH, HARRIS, JOSEPH, WILLIAM, SCOTGEN LIMITED
Application year: 1993
Main classification: C12N15
IPC codes: A61K38, A61K39, A61P31, C07K16, C12N5, C12N15, C12P21